Vaccine News and Research

Latest Vaccine News and Research

FDA approves sBLA for Influenza A (H1N1) 2009 Monovalent Vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.

16 Sep 2009

BioMedReports.Com issues special investigative report on CEL-SCI

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation.

16 Sep 2009

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year," says Professor Dr. Dr. h. c. Stefan H. E. Kaufmann, Director of the Max Planck Institute for Infection Biology in Berlin, at the 2nd European Congress of Immunology ECI 2009.

16 Sep 2009

CIDRAP summit to address employee protection measures during H1N1 pandemic

Business and healthcare leaders looking to fast-track preparedness for the H1N1 pandemic are gathering with infectious disease experts and Fortune 500 planners this month to determine how best to protect their employees and preserve their operations.

16 Sep 2009

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million.

16 Sep 2009

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

VOA News examines the ongoing struggle for Papua New Guinea's health system to treat thousands of people infected by the "simultaneous outbreaks of influenza, dysentery and cholera that have killed about 120 people." The article includes information about the difficulties heath officials are having in assessing the various outbreaks and concerns of medical workers that conditions may soon worsen (Mercer, 9/14).

16 Sep 2009

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

16 Sep 2009

WHO says 3b people worldwide could receive H1N1 vaccine

Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

15 Sep 2009

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.

15 Sep 2009

Members of BCBSF to receive coverage for the administration of the H1N1 vaccine

Blue Cross and Blue Shield of Florida, Inc. (BCBSF) announces today its plans to offer coverage for the administration of the H1N1 vaccine to all members when it becomes commercially available to the public. The vaccine administration will be covered for members whose health care plans cover vaccines, as well as for those members whose plans currently do not include immunizations.

15 Sep 2009

American Lung Association urges families to get immunized against seasonal influenza

The American Lung Association is intensifying its seasonal influenza public education initiative to urge families to get vaccinated as soon as possible. The Faces of Influenza campaign aims to ensure Americans get immunized against seasonal influenza, which each year causes an estimated 36,000 deaths and over 226,000 hospitalizations from the virus and its related complications.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

Vaccine News and Research

Latest Vaccine News and Research

FDA approves sBLA for Influenza A (H1N1) 2009 Monovalent Vaccine

BioMedReports.Com issues special investigative report on CEL-SCI

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

CIDRAP summit to address employee protection measures during H1N1 pandemic

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

WHO says 3b people worldwide could receive H1N1 vaccine

Four H1N1 vaccines approved by FDA

New peptide-based cancer vaccine tested in genital cancer patients

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Members of BCBSF to receive coverage for the administration of the H1N1 vaccine

American Lung Association urges families to get immunized against seasonal influenza

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

FluCide more effective than Tamiflu

Oil-and-water-based nanoemulsion could be more effective for treating burns

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in